Nuformix plc (LON:NFX – Get Free Report) dropped 12.7% during trading on Friday . The company traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.06 ($0.00). Approximately 1,264,138 shares were traded during trading, a decline of 78% from the average daily volume of 5,766,543 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Stock Performance
The firm’s fifty day moving average price is GBX 0.12 and its 200 day moving average price is GBX 0.16. The firm has a market cap of £450,620.50, a P/E ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- How to Invest in Blue Chip Stocks
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Energy and Oil Stocks Explained
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- EV Stocks and How to Profit from Them
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
